{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:34Z","timestamp":1787070874227,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Backgrounds:<\/jats:title>\n                    <jats:p>Non-Hodgkin's lymphoma and Hodgkin's lymphomas (HL) are lymphoid neoplasms. Hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) are viruses that could proliferate in lymphoid tissues. These viruses may cause lymphoproliferative diseases. The aim of this study was to evaluate the seroprevalence of HBV, HCV, and HIV in patients with diffuse large B-cell lymphoma (DLBCL) and HL, to compare the relationship between these two disease groups and to determine the relationship between the three viruses and their characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>The study was a retrospective study. Patients who were followed up in hematology and hepatitis outpatient units between January 01, 2012, and May 01, 2019, were included in the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A statistically significant relationship was observed between the disease groups in terms of hepatitis B surface antigen (HBsAg), hepatitis B core (HBc) IgG antibody, hepatitis B e antigen (HBeAg), and anti-HBe seropositivities (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.006,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.041, and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.014, respectively). There was also a statistically significant relationship between the disease groups in terms of anti-HCV seropositivity (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.029). HBsAg, anti-HBc IgG, HBeAg, anti-Hbe, and HCV seropositivity rates were higher in patients with DLBCL than in patients with HL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These findings suggest that there may be a relationship between hepatitis viruses and DLBCL. Evaluation of HBV and HCV infections in these patients before starting treatment is thought to be beneficial in initiating antiviral prophylaxis to prevent reactivation in seropositive cases. In addition, care should be taken for the development of lymphoma in the follow-up of HCV and HBV infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_465_19","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T07:27:42Z","timestamp":1631777262000},"page":"951-955","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus seroprevalence in patients with diffuse large B cell lymphoma and Hodgkin's lymphoma"],"prefix":"10.4103","volume":"17","author":[{"given":"Duygu","family":"Mert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alparslan","family":"Merdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabahat","family":"Ceken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Sinan","family":"Dal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Ertek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fevzi","family":"Altuntas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20241021","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"R2-20-20241021","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00277-015-2543-4","article-title":"Non-Hodgkin lymphoma in the far East: Review of 730 cases from the international non-Hodgkin lymphoma classification project","volume":"95","author":"Perry","year":"2016","journal-title":"Ann Hematol"},{"key":"R4-20-20241021","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/hon.984","article-title":"Disease patterns in pediatric classical Hodgkin lymphoma: A report from a developing area in Brazil","volume":"29","author":"Barros","year":"2011","journal-title":"Hematol Oncol"},{"key":"R5-20-20241021","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa023141","article-title":"Characteristics of Hodgkin's lymphoma after infectious mononucleosis","volume":"349","author":"Hjalgrim","year":"2003","journal-title":"N Engl J Med"},{"key":"R6-20-20241021","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/infdis\/153.3.471","article-title":"Hepatitis B virus DNA in mononuclear cells and analysis of cell subsets for the presence of replicative intermediates of viral DNA","volume":"153","author":"Yoffe","year":"1986","journal-title":"J Infect Dis"},{"key":"R7-20-20241021","doi-asserted-by":"crossref","first-page":"25061","DOI":"10.18632\/oncotarget.4677","article-title":"Hepatitis B virus-associated diffuse large B-cell lymphoma: Unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin","volume":"6","author":"Deng","year":"2015","journal-title":"Oncotarget"},{"key":"R8-20-20241021","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: An update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"R9-20-20241021","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/gut.2009.192088","article-title":"Occult infection of peripheral B cells by hepatitis C variants which have low translational efficiency in cultured hepatocytes","volume":"59","author":"Durand","year":"2010","journal-title":"Gut"},{"key":"R10-20-20241021","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3109\/10428194.2010.551573","article-title":"Reactivation of hepatitis B virus following bendamustine-containing chemotherapy in a patient with multiple myeloma","volume":"52","author":"Tapan","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"R11-20-20241021","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jhep.2013.03.018","article-title":"Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management","volume":"59","author":"Peveling-Oberhag","year":"2013","journal-title":"J Hepatol"},{"key":"R12-20-20241021","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/ijc.23416","article-title":"Hepatitis C infection and risk of malignant lymphoma","volume":"122","author":"Sch\u00f6llkopf","year":"2008","journal-title":"Int J Cancer"},{"key":"R13-20-20241021","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00001622-199409000-00008","article-title":"Epidemiology of AIDS-related malignancies","volume":"6","author":"Rabkin","year":"1994","journal-title":"Curr Opin Oncol"},{"key":"R14-20-20241021","first-page":"57","article-title":"AIDS-associated malignancies","volume":"35","author":"Akanmu","year":"2006","journal-title":"Afr J Med Med Sci"},{"key":"R15-20-20241021","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<645::AID-IJC6>3.0.CO;2-X","article-title":"Non-Hodgkin's lymphoma among people with AIDS: \u0130ncidence, presentation and public health burden. AIDS\/Cancer Study Group","volume":"73","author":"Cot\u00e9","year":"1997","journal-title":"Int J Cancer"},{"key":"R16-20-20241021","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.7150\/jca.24384","article-title":"Capable \u0131nfection of hepatitis B virus in diffuse large B-cell lymphoma","volume":"9","author":"Wang","year":"2018","journal-title":"J Cancer"},{"key":"R17-20-20241021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jnci.2015.01.004","article-title":"Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: Significance of hepatitis B core antibodies screening","volume":"27","author":"Elbedewy","year":"2015","journal-title":"J Egypt Natl Canc Inst"},{"key":"R18-20-20241021","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.leukres.2013.06.007","article-title":"Hepatitis B infection increases the risk of non-Hodgkin lymphoma: A meta-analysis of observational studies","volume":"37","author":"Dalia","year":"2013","journal-title":"Leuk Res"},{"key":"R19-20-20241021","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1445-5994.2009.02060.x","article-title":"Prevalence of hepatitis B virus infection in non-Hodgkin lymphoma: A systematic review and meta-analysis","volume":"40","author":"Nath","year":"2010","journal-title":"Intern Med J"},{"key":"R20-20-20241021","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/ejh.13300","article-title":"Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma","volume":"103","author":"Zhou","year":"2019","journal-title":"Eur J Haematol"},{"key":"R21-20-20241021","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.7150\/jca.31033","article-title":"Chronic hepatitis B virus infection is associated with a poorer prognosis in diffuse large B-cell lymphoma: A meta-analysis and systemic review","volume":"10","author":"Rong","year":"2019","journal-title":"J Cancer"},{"key":"R22-20-20241021","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cgh.2008.02.011","article-title":"Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the \u0131nternational lymphoma epidemiology consortium","volume":"6","author":"de Sanjose","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R23-20-20241021","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ijc.31110","article-title":"Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients","volume":"142","author":"Hosry","year":"2018","journal-title":"Int J Cancer"},{"key":"R24-20-20241021","doi-asserted-by":"crossref","first-page":"980942","DOI":"10.1155\/2012\/980942","article-title":"HCV and lymphoproliferation","volume":"2012","author":"Zignego","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"R25-20-20241021","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.critrevonc.2019.04.005","article-title":"Heterogeneity and coexistence of oncogenic mechanisms involved in HCV-associated B-cell lymphomas","volume":"138","author":"Carloni","year":"2019","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_465_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:38:02Z","timestamp":1787067482000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_465_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_465_19","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}